lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aardvark Therapeutics, Inc.
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 24, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
February 13, 2026
Aardvark Therapeutics Announces Leadership Appointments
February 13, 2026
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
February 12, 2026